---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-045199"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:00:25.790486+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma doses first three patients in Phase 2 glioblastoma trial; raises $4.5M

## Summary
- First three patients dosed in Phase 2 trial of Ropidoxuridine for glioblastoma; screening for additional patients ongoing.
- Paid off entire $4.3M Senior Secured Convertible Note ahead of March 2025 maturity.
- Completed $4.5M public offering; proceeds to fund clinical trials and working capital.
- Closed $790k convertible note/warrant offering, including $237.5k from CEO Anatoly Dritschilo.
- Cash balance $4.1M as of October 31, 2024.

## SEC filing metadata
- accession: 0001493152-24-045199
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315224045199/0001493152-24-045199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315224045199/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-045199
- JSON: https://secwatch.observer/filing/0001493152-24-045199.json
- Plain text: https://secwatch.observer/filing/0001493152-24-045199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.